Identification of New Markers in the Hypereosinophilic Syndrome
NCT ID: NCT01713504
Last Updated: 2026-01-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
41 participants
INTERVENTIONAL
2010-06-29
2015-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the C5a/C5aR1 Axis in IgG4-associated Disease: a Potential Therapeutic Target
NCT06270524
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
NCT06605378
Gene Polymorphism of IL17 and IL 23
NCT04948515
Investigation of the Influence of the Human Microbiome on Giant Cell Arteritis
NCT06279065
Haufen Diagnostic Biomarkers of BK Renal Disease
NCT01094691
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hypereosinophilic syndrome unexplained
biologie sample
comparison of biomarkers between HES, HE biomarkers data and control arms
Hypereosinophilic syndrome explained
biologie sample
comparison of biomarkers between HES, HE biomarkers data and control arms
Normal rate of eosinophilic
biologie sample
comparison of biomarkers between HES, HE biomarkers data and control arms
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
biologie sample
comparison of biomarkers between HES, HE biomarkers data and control arms
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* virale serology negative or negative result less than 6 months
* virale serology negative for HBV or vaccinated patient
* insured
* virale serology negative or negative result less than 6 months
* negative pregnancy test or female menopause for at least 1 year
Exclusion Criteria
* Refusal or inability to give informed consent
* The hypereosinophilic syndrome explained origin other than than atopy, bullous pemphigoid, the Churg-Strauss syndrome and DRESS
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Lille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lionel Prin, MD PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Lille
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHRU, Hôpital Claude Huriez
Lille, Nord, France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lefevre G, Copin MC, Roumier C, Aubert H, Avenel-Audran M, Grardel N, Poulain S, Staumont-Salle D, Seneschal J, Salles G, Ghomari K, Terriou L, Leclech C, Morati-Hafsaoui C, Morschhauser F, Lambotte O, Ackerman F, Trauet J, Geffroy S, Dumezy F, Capron M, Roche-Lestienne C, Taieb A, Hatron PY, Dubucquoi S, Hachulla E, Prin L, Labalette M, Launay D, Preudhomme C, Kahn JE; French Eosinophil Network. CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder. Haematologica. 2015 Aug;100(8):1086-95. doi: 10.3324/haematol.2014.118042. Epub 2015 Feb 14.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-A00314-53
Identifier Type: OTHER
Identifier Source: secondary_id
2008_29
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.